Malarone slide presentation
XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated overall survival.
1 One Year Post-Exclusivity Adverse Event Review: Linezolid Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
FDA Advisory Committee May 15, 2003 Genentech Marketing Application STN 103976 / 0 Omalizumab Recombinant human anti-IgE for treatment of asthma Efficacy.
XELOX vs. FOLFOX4: survival and response results from XELOX-1 / NO16966, a randomized phase III trial of first-line treatment for patients with metastatic.
